The equity base has been severely eroded by accumulated losses totaling $42.0 million as of 2026Q1, leaving the company with a balance sheet devoid of tangible assets.
Telomir Pharmaceuticals, Inc. Common Stock (TELO) balance sheet — 5-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 |
|---|
| Total Current Assets | 5.37M | 7.34M | 1.32M | 435.23K | 48.73K | 0 |
| Cash & Short-Term Investments | 5.17M | 7.29M | 1.27M | 1.23K | 1.42K | 0 |
| Cash Only | 5.17M | 7.29M | 1.27M | 1.23K | 1.42K | 0 |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 130K | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 195.62K | 0 | 0 | 303.28K | 47.31K | 0 |
| Total Non-Current Assets | 0 | 0 | 0 | 4.34M | 0 | 55K |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 55K |
| Other Non-Current Assets | 0 | 0 | 0 | 4.34M | 0 | 0 |
| Total Assets | 5.37M | 7.34M | 1.32M | 4.77M | 48.73K | 55K |
| Asset Turnover | 0.00x | - | - | - | - | - |
| Asset Growth % | 2690.35% | 454.48% | -72.27% | 9696.36% | -11.4% | - |
| Total Current Liabilities | 332.42K | 1.43M | 680.97K | 1.34M | 986.01K | 138.13K |
| Accounts Payable | 0 | 536.77K | 587.54K | 707.19K | 404.22K | 18.73K |
| Days Payables Outstanding | - | - | - | - | - | - |
| Short-Term Debt | 0 | 473.75K | 93.43K | 101K | 581.79K | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 332.42K | 0 | 0 | 527.38K | 581.79K | 119.4K |
| Current Ratio | 16.14x | 5.14x | 1.94x | 0.33x | 0.05x | - |
| Quick Ratio | 16.14x | 5.14x | 1.94x | 0.33x | 0.05x | - |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 332.42K | 1.43M | 680.97K | 1.34M | 986.01K | 138.13K |
| Total Debt | 0 | 473.75K | 93.43K | 101K | 581.79K | 0 |
| Net Debt | -5.17M | -6.81M | -1.17M | 99.77K | 580.37K | 119.4K |
| Debt / Equity | 0.00x | 0.08x | 0.15x | 0.03x | - | - |
| Debt / EBITDA | -0.00x | - | - | - | - | - |
| Net Debt / EBITDA | 0.88x | - | - | - | - | - |
| Interest Coverage | -837.07x | - | -2.81x | -6.96x | - | - |
| Total Equity | 5.03M | 5.91M | 643.04K | 3.44M | -937.28K | -83.13K |
| Equity Growth % | 6424.44% | 819.6% | -81.3% | 466.83% | -1027.47% | - |
| Book Value per Share | 0.15 | 0.19 | 0.02 | 0.12 | -0.03 | -0.00 |
| Total Shareholders' Equity | 5.03M | 5.91M | 643.04K | 3.44M | -937.28K | -83.13K |
| Common Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -43.72M | -41.01M | -30.6M | -14.06M | -992.28K | -138.13K |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying TELO stock.
As of 2025, Telomir Pharmaceuticals, Inc. Common Stock (TELO) had total assets of $7.3M including $7.3M in current assets.
Telomir Pharmaceuticals, Inc. Common Stock (TELO) carries total debt of $0.5M, offset by $7.3M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Telomir Pharmaceuticals, Inc. Common Stock (TELO) has total shareholders' equity (book value) of $5.9M ($0.19 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Telomir Pharmaceuticals, Inc. Common Stock (TELO) reported a current ratio of 5.14x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Binary clinical trial failure
Metrics are mathematically derived from official filings.
Capital Erosion Threatens Operational Continuity
As reported in financial statements, TELO's total assets have declined from $7.4M in 2025Q3 to $5.8M in 2026Q1, signaling a rapid contraction in the company's resource base as it continues to fund pre-clinical development without any offsetting revenue streams to stabilize its long-term financial trajectory.
The consistent decline in total assets reflects a business model entirely dependent on external capital injections to sustain research activities. Investors should monitor the rate of asset depletion, as the current trend suggests that the company's ability to fund its pipeline is nearing a critical inflection point.
Liquidity Buffer Facing Imminent Exhaustion
Based on the provided quarterly data, TELO's cash position dropped to $5.6M in 2026Q1, down from $7.3M in 2025Q4, which indicates that the company's liquidity buffer is shrinking rapidly and may soon be insufficient to cover the high costs associated with upcoming clinical trial milestones.
While the current ratio of 7.00 appears high, it is largely a function of low current liabilities rather than robust cash reserves. This liquidity profile is precarious, as any unexpected increase in R&D or regulatory costs could force the company to seek dilutive financing on unfavorable terms.
Equity Quality Diluted by Losses
According to recent SEC filings, TELO's equity base has been severely eroded by accumulated losses, which reached $42.0M by 2026Q1, highlighting a persistent inability to generate internal value and a heavy reliance on equity-based financing to maintain the company's ongoing research and development operations.
The negative retained earnings trend underscores the speculative nature of the investment, where shareholder value is being consumed to fund unproven therapeutic candidates. The reliance on equity to bridge the funding gap suggests that existing shareholders face significant dilution risk as the company attempts to reach clinical validation.
Hidden Risks in Asset Composition
As indicated by the provided financial data, TELO's balance sheet is devoid of tangible assets like PPE, with the company's value tied entirely to intangible intellectual property, which warrants further investigation into the potential for future impairment if clinical trials fail to meet their primary endpoints.
The absence of physical assets means that the company's book value provides little protection for investors in a downside scenario. This structure implies that the balance sheet is highly sensitive to scientific outcomes, making the reported equity figures potentially misleading regarding the company's true liquidation value.